drugset / Trial / NCT01568762

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

NCT01568762

Phase 1 Completed 50 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindOther

Summary

This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to moderate asthma.

Timeline

Start
2010-10
Primary completion
2011-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject QAX576 Monoclonal antibody Intravenous
Subject VAK694 Unknown Intravenous

Indications